Thursday, June 01, 2023 2:31:19 AM
Fudsteerville can kma. We were right
https://www.proactiveinvestors.com/companies/news/1016408/revive-therapeutics-staying-the-course-on-phase-3-trial-of-bucillamine-in-covid-19-patients-after-meeting-with-fda-1016408.html
$RVVTF is staying-the-course-on-phase-3-trial-of-bucillamine-in-covid-19-patients-after-meeting-with-fda
https://www.proactiveinvestors.com/companies/news/1016408/revive-therapeutics-staying-the-course-on-phase-3-trial-of-bucillamine-in-covid-19-patients-after-meeting-with-fda-1016408.html
$RVVTF is staying-the-course-on-phase-3-trial-of-bucillamine-in-covid-19-patients-after-meeting-with-fda
Bullish
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
